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Abstract. Humans, domestic animals, orchard crops, and ornamental plants are commonly treated
with antibiotics in response to bacterial infection. By curing infectious individuals, antibiotic
therapy might limit the spread of contagious disease among hosts. But antibiotic suppression of
within-host pathogen density might also reduce the probability that the host is otherwise removed
from infectious status before recovery. When rates of both recovery and removal (isolation or
mortality) depend directly on within-host density, antibiotic therapy can relax the removal rate
and so increase between-host disease transmission. In this paper a deterministic within-host
dynamics drives the infectious host’s probability of infection transmission, as well as the host’s
time-dependent probability of surviving to recovery. The model varies (1) inoculum size, (2) the
time elapsing between infection and initiation of therapy, (2) antibiotic efficacy, and (3) the
size/susceptibility of groups encountered by an infectious host. Results identify conditions where
antibiotic treatment simultaneously increases host survival and increases the expected number of
new infections. That is, antibiotics might convert a rare, serious bacterial disease into a common,
but treatable infection.
Keywords: group size; inoculum; mortality hazard; pathogen extinction; within-host dynamics
1 Introduction
Antibiotics are administered routinely to humans, agricultural/pet animals, and certain plants
[McManus et al. 2002, D’Agata et al. 2008, Saenz and Bonhoeffer 2013], and antibiotic therapy
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remains both a scientific and societal issue [Read et al. 2011, Levin et al. 2014]. Beyond concerns
about the evolution of resistance [Weinstein et al. 2001, Lopatkin et al. 2017], antibiotics present a
range of challenging questions, including optimizing trade-offs between antibacterial efficacy and its
toxicity to the treated host [Geli et al. 2012]. This paper offers a simple model where an
antibiotic’s direct impact on within-host pathogen dynamics indirectly affects transmission between
hosts [Mideo et al. 2008, Childs et al. 2019]. At the within-host level, the timing of antibiotic
administration governs the duration of infection, the chance the host survives disease, and the
host’s infectiousness given random, socially structured contacts with susceptible individuals. By
assuming that recovery via therapy and host mortality depend differently on the within-host state,
the results show when an antibiotic may simultaneously increase both survival of an infected
individual and the expected number of secondary infections.
1.1 The infectious period
Efficacious antibiotics, by definition, reduce within-host pathogen density
[Levin and Udekwu 2010], and for some infections, increase the host’s probability of surviving
disease. Benefit to the treated individual is often equated with an epidemiological benefit; if
antibiotics shorten the infectious period, the count of infections per infection could decline
[Levin et al. 2014]. This interpretation follows from SIR compartment models, where neither
host-mortality rate nor the antibiotically-induced recovery rate depends explicitly on within-host
pathogen density. Antibiotics are assumed to reduce duration of the infectious period and have no
effect on transmission intensity. By extension, antibiotics may then reduce pathogen transmission.
Can antibiotic therapy increase the expected length of the infectious period? Relationships
among transitions in host status must often depend on a within-host dynamics [Mideo et al. 2008].
As infection progresses, the pathogen density’s trajectory should drive temporal variation in the
rate of host mortality, the rate of recovery from disease, as well as the rate at which infection is
transmitted [VanderWall and Ezenwa 2016]. For many human bacterial infections, an individual
can still transmit the pathogen after beginning antibiotic therapy [Moon 2019]. Common infections
remain transmissible for a few days to two weeks [Siegel et al. 2007]; although not addressed here,
sexually transmitted disease may be transmitted for months after antibiotic therapy has begun
[Falk et al. 2015]. Therapeutic reduction in pathogen density might cure the host, while allowing
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the host to avoid hospitalization, isolation, etc [DeRigne et al. 2016]. The result can be a longer
period of infectious contacts and, consequently, more secondary infections.
This paper assumes that with or without antibiotic treatment, an infectious host may be
removed by mortality. As a convenience, mortality includes any event that ends infectious contacts
with susceptible hosts, without the antibiotic curing the disease. That is, the between-host
hospitalization/isolation for humans, quarantine for agricultural animals, and extirpation for plants
are dynamically equivalent to mortality. The model assumes that an antibiotic, by deterring
within-host pathogen growth, increases the waiting time for removal via mortality, but an increase
in antibiotic efficacy reduces the time until the host is cured. The interaction affects the count of
secondary infections; the reproduction numbers (before and after therapy begins) identify
conditions where an antibiotic increases the spread of disease.
1.2 Susceptible group size
This paper also examines effects of structured contacts on probabilistic disease transmission
[Eames and Keeling 2002, van Baalen 2002, Caraco et al. 2006]. Social group size can affect
contacts between infectious and susceptible hosts, and so govern the spread of infection at the
population scale [Turner et al. 2008, Caillaud et al. 2013, Caraco et al. 2016]. The model asks how
the number of hosts per encounter with an infectious individual (with the product of encounter rate
and group size fixed) impacts the variance in the count of secondary infections, which can influence
the likelihood that a rare infection fails to invade a host population [Keeling and Grenfell 1998].
1.3 Organization
The model treats pathogen growth and its antibiotic regulation deterministically
[D‘Argenio et al. 2001, White et al. 2012]. Host survival and transmission of infection are treated
probabilistically [Whittle 1955, Caillaud et al. 2013, Lahodny et al. 2015]. The first step is to solve
the simple within-host model for the time-dependent density of a bacterial pathogen; the host’s
mortality hazard and the infection-transmission process then depend on the within-host result.
Pathogen density increases from time of infection until antibiotic treatment begins, given host
survival. The antibiotic then reduces pathogen density until the host is either cured or removed.
Counts of secondary infections require the temporal distribution of infectious contacts, since the
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probability of transmission depends on the time-dependent pathogen state of the infectious host
[Strachan et al. 2005, VanderWall and Ezenwa 2016]. The same temporal distributions lead to
expressions for mean inoculum sizes for the next generation of within-host growth. The results
explore effects of antibiotics and inoculum size [Steinmeyer et al. 2010] on disease reproduction
numbers, host survival, and pathogen extinction.
2 Within-host dynamics: timing of antibiotic treatment
Bt represents the within-host bacterial density at time t; B0 is the inoculum size. Antibiotic
treatment begins at time tA > 0. The model refers to Bt as pathogen state. The cumulative
pathogen density Ct is termed pathogen load. Table 1 defines model symbols used in this paper.
The model assumes that the pathogen grows exponentially prior to treatment
[D‘Argenio et al. 2001, Lindberg et al. 2018]; Bt = B0e
rt for t ≤ tA. The intrinsic growth rate
r > 0 is the difference between the replication and mortality rates per unit density. The latter rate
may reflect a nonspecific host immune response [Pilyugin and Antia 2000]; the model does not
include an explicit immune dynamics, to focus on effects of antibiotic timing and efficacy.
Recognizing that resource limitation sometimes decelerates pathogen growth
[D’Agata et al. 2008, Geli et al. 2012], Appendix A assumes logistic within-host dynamics.
Most antibiotics increase bacterial mortality [Regoes et al. 2004, Levin and Udekwu 2010],
though some impede replication [Austin et al. 1998]. When a growing bacterial population is
treated with an efficacious antibiotic, bacterial density (at least initially) declines exponentially
[Tuomanen et al. 1986, Balaban et al. 2004, Wiuff et al. 2005]. Hence, the model below assumes
exponential decay of Bt during therapy; the Discussion acknowledges complications that might
arise during treatment.
2.1 Antibiotic concentration and efficacy
Assumptions concerning antibiotic efficacy follow from Austin et al. [1998]. Given host survival
through time t > tA, the total loss rate per unit bacterial density is µ+ γ(At), where At is the
plasma concentration of the antibiotic, and γ maps antibiotic concentration to bacterial mortality.
Assume that the antibiotic is effectively ‘dripped’ at input rate DA. Plasma antibiotic
4
Symbols Definitions
Within-host scale
t Time since infection (hence, age of infection)
Bt Bacterial density at time t after infection, pathogen state
B0 Inoculum size
r Pathogen‘s intrinsic rate of increase
Ct Cumulative pathogen density, pathogen load
γ∗A Density-independent bacterial mortality rate due to antibiotic
tA Age of infection when antibiotic initiated, given host survival
θ Proportionality of inoculum to pathogen density at time of cure
tC Age of infection when host cured, given survival
Individual host scale
ht Stochastic disease-mortality rate of host that has survived to time t
φ Mortality-hazard prefactor
η Virulence parameter
Lt Probability host remains alive (and infectious) at time t ≤ tC
Between-host scale
λ/G Stochastic contact rate, group of G susceptibles (G = 1, 2, ...)
νt Conditional probability of infection, given contact
ξ Infection susceptibility parameter
pt Probability susceptible infected at time t; pt = Ltνt
Pj Time-averaged probability of infection at contact
before/after (j = 1, 2) therapy begins
R1 Expected new infections per infection before tA
R2 Expected new infections per infection on (tA, tC)
R0 R1 +R2
B0j Inoculum transmitted, before/after (j = 1, 2) therapy begins
Table 1: Definitions of model symbols, organized by scale.
concentration decays through both metabolism and excretion; let kA represent the total decay rate.
Then, dAt/dt = DA − kAt, so that At = (DA/k) (1− e
−kt), for t > tA. Antibiotic concentration
generally approaches equilibrium much faster than the dynamics of bacterial growth or decline
[Austin et al. 1998]. Separating time scales, a quasi-steady state assumption implies the
equilibrium plasma concentration of the antibiotic is A∗ = DA/k.
Bacterial mortality increases in a decelerating manner as antibiotic concentration increases
[Mueller et al. 2004, Regoes et al. 2004]. Using a standard formulation [Geli et al. 2012]:
γ(At) = Γmax At/
(
a1/2 +At
)
; t > tA (1)
where γ(At) = Γmax/2 when At = a1/2. Applying the quasi-steady state assumption, let
γ∗A = γ(A
∗). Since the antibiotic is efficacious, γ∗A > r. If antibiotic concentration cannot be treated
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as a fast variable, time-dependent analysis of concentration is available [Austin et al. 1998].
2.2 Antibiotic treatment duration
From above BtA = B0e
rtA . If the host survives beyond tA, the within-host pathogen density
declines as dBt/dt = − (γ
∗
A − r)Bt. Then:
Bt = BtA exp [−(γ
∗
A − r)(t− tA)] = B0 exp [rt− γ
∗
A(t− tA)] ; t > tA (2)
Given that the host is not otherwise removed, antibiotic treatment continues until the host is
cured at time tC > tA. tC is the maximal age of infection; that is, a surviving host’s period of
infectiousness ends at tC . In terms of pathogen density, B(tC) = B0/θ, where θ ≥ 1. Since tC > tA,
cure by the antibiotic implies:
B0/θ = B0 exp [rtC − γ
∗
A(tC − tA)] ⇒ tC =
γ∗AtA + lnθ
γ∗A − r
(3)
If the cure requires only that Bt return to the inoculum size, then θ = 1, and
tC = γ
∗
AtA/(γ
∗
A − r) > tA. For any θ ≥ 1, a surviving host is cured sooner as antibiotic efficacy (γ
∗
A)
increases, when treatment begins earlier, and as the pathogen’s growth rate (r) decreases. Instead
of defining recovery via therapy as a pathogen density proportional to B0, suppose that the host is
cured if the within-host density declines to B(t > tA) = B˜ ≤ B0. Let θ˜ = B˜/B0. The associated
maximal age of infection is t˜ = (γ∗AtA − lnθ˜)/(γ
∗
A − r). t˜ depends on γ
∗
A, tA and r just as tC does,
and numerical differences will be small unless B0 and B˜ differ greatly. Computations below use tC .
3 Host survival
As noted above, mortality refers to any event, other than antibiotic cure, that ends the host’s
infectious period; the complement is survival. Mortality occurs probabilistically and becomes more
likely as disease severity increases. The term “pathogen burden” refers to a functional scaling of
pathogen density to disease severity suffered by an infected host [Medzhitov et al. 2012]. Host
mortality hazard (especially for virulent disease) should increase with either pathogen state Bt or
pathogen load Ct [Lindberg et al. 2018]. But cumulative pathogen density Ct must increase
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monotonically with time since infection; pathogen state Bt declines after antibiotic therapy begins,
and host mortality should decline as a consequence. Therefore, the model assumes that mortality
hazard at any time t is an increasing function of pathogen density Bt.
Mortality occurs as the first event of a nonhomogeneous Poisson process; ht is the instantaneous
mortality hazard at time t [Bury 1975]. Lt is the probability that the host, infected at time 0,
remains alive and infectious at time t ≤ tC . Prior to initiation of therapy:
Lt ≡ exp
[
−
∫ t
0
hτ dτ
]
; t ≤ tA (4)
and (1− Lt) is the probability the host dies before time t. The assumed mortality hazard is
ht = φB
η
t ; φ, η > 0. η is the virulence parameter; it scales each pathogen-density unit’s severity
to the host.
Given ht, survival probability prior to antibiotic treatment is:
Lt = exp
[
−φBη0
∫ t
0
eηrτdτ
]
= exp
[
φBη0
ηr
]/
exp
[
φBηt
ηr
]
; t ≤ tA (5)
where the numerator is a positive constant, and the denominator strictly increases before the
antibiotic begins. The form of Eq. 5 shows that prior to tA, Lt scales as the right tail of a type-I
Extreme Value approximation for the minimal realization of a probability density decaying at least
as fast as an exponential [Bury 1975]. This observation follows from the exponential increase in
mortality hazard ht prior to therapy. An equivalent, useful form for host-survival probability before
treatment is:
Lt = exp
[
−
φ
ηr
(Bηt −B
η
0 )
]
; t ≤ tA (6)
L(t = 0) = 1, and host survival declines as t increases.
3.1 Survival during antibiotic therapy
If an infectious host begins antibiotic therapy, the individual must have survived to tA; the
associated probability is LtA . From above, an antibiotically treated host has instantaneous
mortality hazard:
ht = φB
η
tA
e−η(γ
∗
A
−r)(t−tA); t > tA (7)
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The probability that the host remains alive and infectious at any t, where tA < t < tC , is the
probability of surviving from infection to initiation of treatment, LtA , times the probability of
surviving from tA to t, given that the host remains alive at tA. Using Eq. 7, host survival during
therapy is:
Lt = LtA exp
[
−φBηtA
∫ t
tA
e−η(γ
∗
A
−r)(τ−tA)dτ
]
= LtA exp
[
φBηt
η(γ∗A − r)
]/
exp
[
φBηtA
η(γ∗A − r)
]
; t > tA (8)
where the denominator is a constant. Then survival during therapy is:
Lt = LtA exp
[
−
φ
η(γ∗A − r)
(
BηtA −B
η
t
)]
; t > tA (9)
where BtA > Bt, and LtA = exp
[
−(φ/ηr)
(
BηtA −B
η
0
)]
.
Greater antibiotic efficacy slows decay of host survival after treatment begins. Delaying the
initiation of treatment (i.e., increasing tA) both decreases the chance that the host survives long
enough to be treated, and (given survival to tA) decreases the probability of survival to any time t
where tA < t ≤ tC . For the same range of t, the mortality probability density is −dLt/dt
[Buford and Hafley 1985].
Figure 1 sketches surfaces of the probability that the host survives until cured (at time tC). Both
plots show the loss of survival associated with delay prior to antibiotic treatment. The upper plot
shows the increase in survival due to increased antibiotic efficacy across intermediate levels of tA.
The lower plot shows how increasing virulence diminishes host survival. The model’s simple
within-host pathogen dynamics allows straightforward expressions for host survival from the
initiation of pathogen growth to loss of infectiousness when the host is cured by therapy. Any
significance of this pathogen-host model lies in implications for infection transmission.
4 Transmission
The focal infective contacts susceptible hosts as groups. Each group has the same size G; often
G = 1. Contacts occur as a Poisson process, with constant probabilistic rate λ/G; the contact rate
does not depend on time or pathogen state Bt. Then the expected number of individuals contacted
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Figure 1: Host survival to tC . Upper plot: L(tC) declines rapidly as tA increases. At intermediate
levels of tA, greater antibiotic efficacy γ
∗
A strongly increases probability host will survive infection.
η = 1.2. Lower plot: L(tC) again declines as tA increases. At most tA levels, host survival declines
with greater virulence. γ∗A = 0.6. Both plots: B0 = 10
3, r = 0.4, φ = 10−7.
on any period is independent of susceptible-host group size G.
Given both survival of the infectious host and a transmission-contact at time t, associate a
random, dichotomous outcome It(j) with susceptible host j; j = 1, 2, ..., G. It(j) = 0 if no
transmission occurs, and It(j) = 1 if a new infection occurs, independently of all other contact
outcomes. A contact, then, equates to G independent Bernoulli trials, and the number of new
infections, per contact, follows a binomial probability function with parameters G and pt. That is,
pt = Pr[It = 1], so that 1− pt = Pr[It = 0]. pt is the conditional probability that any host j
acquires the infection, given contact at time t. The model writes pt as a product: pt = Ltνt. The
infected host’s time-dependent survival, an unconditional probability, Lt weighs “births” of new
infections upon contact [Day et al. 2011]. νt is the conditional probability that any host j is
infected at time t given that the infectious host survives to time t, and contact occurs.
Importantly, both Lt and νt depend on within-host pathogen density Bt [Mideo et al. 2008].
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Given an encounter, the transmission probability νt assumes a dose-response relationship
[Strachan et al. 2005, Kaitala et al. 2017]. Following a preferred model [Tenuis et al. 1996],
νt = 1− exp[−ξBt], where ξ is the susceptibility parameter. Then pt = Lt(1− e
−ξBt). νt
decelerates with Bt since dispersal-limited reproduction or infection saturates with propagule
number [Keeling 1999, Dieckmann et al. 2000, Korniss and Caraco 2005]. Note that ∂νt/∂Bt > 0,
and ∂ht/∂BT > 0. An increase in the transmission probability, as a consequence of a greater
within-host pathogen density, is constrained by greater host mortality, a condition generally
recognized as important for the evolution of intermediate disease virulence
[van Baalen 2002, Alizon and van Baalen 2008, Cressler et al. 2015].
4.1 New-infection probabilities: before and during treatment
New infections occur randomly, independently both before and after treatment begins. Since
dBt/dt changes sign at tA, let R1 represent the expected number of new infections on (0, tA]; let
R2 be the expected number of new infections on (tA, tC ]. For simplicity, refer to these respective
time intervals as the first and second period. R0 is the expected total number of new infections per
infection; R0 = R1 +R2.
From above, encounters with the infectious host occur as a Poisson, hence memoryless, process.
Suppose that N such encounters occur on some time interval (tx, ty). By the memoryless property,
the times of the encounters (as unordered random variables) are distributed uniformly and
independently over (tx, ty) [Ross 1983]. Uniformity identifies the time averaging for the conditional
infection probability pt. For the first period, the unconditional (i.e., averaged across the initial tA
time periods) probability of infection at contact is P1:
P1 =
1
tA
∫ tA
0
pτ dτ =
1
tA
∫ tA
0
Lτ (1− e
−ξBτ )dτ
=
(
exp
[
φB0
ηr
]/
tA
) (∫ tA
0
exp
[
−
φBητ
ηr
]
dτ −
∫ tA
0
exp
[
−
φBητ
ηr
− ξBτ
]
dτ
)
(10)
where Bτ = B0e
rτ .
For the second period, averaging uniformly yields P2, the averaged infection probability after
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treatment begins:
P2 =
(
LtA
tC − tA
/
exp
[
φBηtA
η(γ∗A − r)
]) (∫ tC
tA
exp
[
φBητ
η(γ∗A − r)
]
dτ −
∫ tC
tA
exp
[
φBητ
η(γ∗A − r)
− ξBτ
]
dτ
)
(11)
where LtA is given above, and Bτ is given by Eq. 2. Symmetry of the minus signs in the
exponential terms of Eqq. 10 and 11 results because Bt increases until tA and declines thereafter.
Biologically, P1 and P2 collect the pleiotropic effects of within-host density, modulated by
antibiotic treatment, on between-host transmission of infection.
4.2 Secondary infection inocula
The memoryless property allows a comment on inoculum size across secondary infections. Suppose
the inoculum size for a secondary infection transmitted at time t is proportional to Bt. From the
preceding analysis, inoculum size must be weighed by both host survival and infectiousness. Let
B01 be the expected inoculum size for secondary infections transmitted before tA, and let B02 be
expected inoculum size for secondary infections transmitted during the antibiotic therapy:
B01 ∝
B0
tA
∫ tA
0
Lτ (1− e
−ξBτ ) erτ dτ
B02 ∝
B0
tC − tA
∫ tC
tA
Lτ (1− e
−ξBτ ) erτ−γ
∗
A
(τ−tA) dτ (12)
Eq. 12, in a sense, completes the cycle from pathogen growth within the first host to average
properties of the next generation of within-host growth. Emphasizing that second-generation
inocula depend on the unconditional probability of infection at contact, B01 can be written:
B01 ∝
(
B0 exp
[
φB0
ηr
]/
tA
) (∫ tA
0
exp
[
rτ −
φBητ
ηr
]
dτ −
∫ tA
0
exp
[
rτ −
φBητ
ηr
− ξBτ
]
dτ
)
(13)
B02 follows similarly from P2.
4.3 R0
For each of the two periods, the number of infections sums a random number of random variables.
Each element of the sum is a binomial variable with expectation GPz and variance GPz(1− Pz),
where z = 1, 2. The number of encounters with susceptible hosts is a Poisson random variable with
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expectation and variance during the first period (λ/G)tA, and expectation during the second
period (λ/G)(tC − tA). Let X1 be the random count of new infections during the first period, and
let X2 be the second-period count. Then from the time of infection until antibiotic treatment
begins, R1 = E[X1] = λP1tA, and V [X1] = R1[1 + P1(G− 1)]. Then, R2 = E[X2] = λP2(tC − tA),
and the variance of X2 is R2[1 +P2(G− 1)]. Note that if G = 1, each Xz is Poisson with equality of
expectation and variance. By construction, the expected number of infections both before and after
antibiotic treatment begins does not depend on group size G. But each variance of the number of
new infections increases with group size. Finally, the total number of new infections per infection
has expectation R0:
R0 = E[X1 +X2] = λ [P1tA + P2(tC − tA)] (14)
The variance of the total number of new infections is V [X1 +X2] = R0 + (G− 1)[P1R1 + P2R2].
Since group size affects only the variance of the reproduction numbers, any increase in group size
can increase Pr[X1 +X2 = 0], the probability of no new infections, even though R0 > 1. No new
infections requires that each Xz = 0; z = 1, 2. The probability of no pathogen transmission at a
single encounter is (1−Pz)
G, since outcomes for the G susceptible hosts are mutually independent.
Given n encounters in period z, the conditional probability of no new infections during that period
is Pr[Xz = 0 | n] = [(1− Pz)
G]n. Then, unconditionally:
Pr[Xz = 0] =
∞∑
n=0
[(1− Pz)
G]nPr[n] (15)
Since (1− Pz)
G < 1, Pr[Xz = 0] is given by the probability generating function for n, evaluated at
(1− Pz)
G. From above, n is Poisson with parameter (λ/G)tA during the first period. Then:
Pr[X1 = 0] = exp
[
(λ/G)tA([1− P1]
G − 1)
]
(16)
For the second period, Pr[X2 = 0] = exp
[
(λ/G)(tC − tA)([1 − P2]
G − 1)
]
. Each Pr[Xz = 0]
increases as G increases; the group-size effect is stronger as the infection probability Pz increases.
The probability that no new infection occurs is, of course, the product of the independent
probabilities.
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5 Numerical Results
Plots in Fig. 2 show the sort of result motivating this paper. Consider first rapid initiation of
antibiotic therapy (tA < 5 in the example). Then R0 > 1, and the disease may advance when rare.
But delaying therapy sufficiently renders R0 < 1, so that the disease may fail to invade a
susceptible population. In this example, for tA > 10, the results equate essentially to no antibiotic
therapy (LtA ≈ 0; R2 = 0), and R0 < 1.
Why does spread of disease in the example require use of the antibiotic and early initiation of
therapy? A small tA, hence a low BtA , maintains a reduced within-host density and a consequently
reduced mortality hazard for t > tA. The host’s chance of being cured, rather than being removed
by mortality, increases. Therapy begun at low tA cures the host sooner, but (on average) leaves the
host infectious longer. The latter effect increases R0 in the example. Earlier initiation of treatment
must reduce R1. The spread of infection among hosts, for low tA, is due more to transmission
during antibiotic treatment; R0 and R2 reach their respective maximum at nearly the same tA
value. Given contact at t > tA, the reduction in νt due the the antibiotic’s regulation of within-host
pathogen density is more than compensated by the increase in Lt. The focal point is that R0 < 1
with no antibiotic therapy, though R0 can exceed 1 with therapy.
If avoiding removal through the antibiotic treatment implies avoiding death, the first infected
host obviously benefits. But there can be a significant cost at the among-host scale as the infection
spreads. A rare, fatal infection in the absence of antibiotics (R0 < 1) can become a common,
through treatable infectious disease when antibiotic therapy begins soon after initial infection.
Fig. 2 also verifies how susceptible-host group size impacts the probability of an infection
advancing among hosts. Model structure makes R0 independent of G, but larger groups increase
the variance in the total count of infections per infection. As a consequence, the probability that
no new infections occur (pathogen “extinction”) increases strongly with the size of susceptible
groups. Even for the tA level maximizing R0 in Fig. 2, sufficiently large group size assures that
pathogen extinction is more likely than spread of infection.
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Figure 2: Early antibiotic therapy promotes infection transmission. Top row. Left: R1 infections
before tA. Middle: R2 infections after antibiotic started. Right: Total variance (before and after tA)
in number of secondary infections. Solid line is G = 1; dashed line is G = 10. Bottom row. Left:
R0, total infections per infection. Middle: Solid line is LtA ; dotted line is LtC , the probability that
the host survives until cured, given therapy initiated at tA. Ordinate has logarithmic scale. Right:
Probability of no secondary infection transmitted from infectious host. Solid line is G = 1; dashed
line is G = 10. All plots: B0 = 10
4, r = 0.3, φ = 10−5, γ∗A = 0.35, θ = η = 1, ξ = 0.9, and λ = 0.2.
5.1 Antibiotic efficacy, host survival and R0
The preceding results indicate that the time since infection when antibiotic therapy begins can
affect the number of secondary infections non-monotonically. This subsection first considers how
inoculum size can affect R0 and host survival.
Variation in inoculum size can impact pathogen growth, any host immune response, and host
infectiousness [Steinmeyer et al. 2010]. That is, inoculum size, through effects on within-host
processes, should in turn influence transmission of new infections. Fig. 3 simultaneously varies the
inoculum B0 and antibiotic efficacy γ
∗
A. Dependent quantities are R0 and the probability that an
infected host is cured by the antibiotic (LtC ); results were calculated for a smaller and larger tA.
For the figure’s parameter values, R0 (upper left plot) reaches a maximum at low antibiotic
efficacy and small inoculum size. The plot shows results for tA = 4; the surface has the same shape
for smaller and larger tA levels. Not surprisingly, R0 always decreases as γ
∗
A increases. Note that
the effect of increased efficacy, observed for these parameters, does not mean that antibiotics
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Figure 3: Effects of varying γ∗A and B0. Top row. Left: R0 for tA = 4. Secondary-infection expec-
tation declines strictly monotonically with antibiotic efficacy, and with inoculum size. Right: ∆R0
is R0 for low tA minus R0 for high tA. For medium and larger B0, combined with lower antibi-
otic efficacy, earlier treatment generates more secondary infections. Sufficiently increased antibiotic
strength, however, reverses the difference between R0 values. Bottom row. Left: Probability
treated host survives until cured, low tA. Right: Probability host survives until cured, high tA. Low
tA = 4; high tA = 8. All plots: r = 0.3, φ = 10
−6, θ = η = 1, ξ = 0.7, λ = 0.4, and G = 3.
always deter the spread of infection.
R0 also declines as B0 increases; the rate of decline is roughly proportional to R0. When (γ
∗
A − r)
is small, low antibiotic efficacy implies that host mortality should be more probable than is
therapeutic cure. Increasing B0 increases Bt for all t ≤ tC ; mortality hazard ht increases as a
consequence. For these parameters, where susceptibility ξ is comparatively large, any increase in
the transmission probability νt with Bt does not compensate for the reduction in host survival Lt;
a larger inoculum decreases the expected number of secondary infections.
The two lower plots in Fig. 3 verify that the chance of surviving until cured declines as B0
increases. Note the clear quantitative differences between the two LtC -surfaces. For any
(B0, γ
∗
A)-combination, the host’s survival probability is greater for low tA (tA = 4) than for high tA
(tA = 8). For a serious infection, the host should then ‘prefer’ earlier initiation of therapy.
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The upper right plot in Fig. 3 shows the difference between R0 values for the two tA levels;
∆R0 = R0(tA = 4)−R0(tA = 8). When the antibiotic has greater efficacy (γ
∗
A ≥ 0.5) ∆R0 < 0.
Hence the lesser tA level increases host survival and decreases the expected number of secondary
infections. However, if the antibiotic has lower efficacy (γ∗A ≤ 0.4), ∆R0 > 0 for sufficiently large
B0. Earlier treatment still increases survival of the infected host, but now increases R0. Where the
infected host has the most to gain from earlier therapy (survival difference), the infection will
spread the fastest.
5.2 Inoculum size, susceptibility, and R0
The decline in the expected number of secondary infections with increased inoculum size may seem
counterintuitive. The example above demonstrated that for higher susceptibility ξ the chance of
transmission given contact saturates with Bt (hence with B0), while mortality hazard continues to
increase with Bt. To clarify and emphasize the impact of inoculum size on R0, consider variation in
R0 as B0 and tA vary simultaneously, at two levels of susceptibility.
Figure 4 displays contours of R0 values as functions of tA and B0. The upper plot assumes
higher susceptibility; consequently, R0 > 1 everywhere in the plot. For any inoculum size R0 first
increases and then decreases as tA increases; recall explanation of Fig. 2. For any tA, R0 declines
strictly monotonically as B0 increases; recall Fig. 3. It is worth noting that these patterns persist
with more than a 10-fold increase in antibiotically induced mortality.
The lower plot in Fig. 4 assumes lower susceptibility. For combinations of lesser tA and smaller
B0, R0 < 1. The between-plot difference of significance is that for lower tA values, R0 initially
increases with inoculum size, before declining. Hence, for diseases capable of rapid advance among
hosts, R0 should vary inversely with inoculum size. But for infectious diseases near the threshold
R0 = 1, larger inocula might increase R0.
5.3 Group size, R0 and pathogen ‘extinction’
Fig. 5 shows how varying both R0 and susceptible-group size G affects the probability that the
focal host transmits no secondary infections. Fixing G in any of the plots, pathogen-extinction
probability declines monotonically as R0 increases. Given an R0, the chance of pathogen extinction
increases strictly monotonically as G increases; see Eq. 16. The decline in pathogen-extinction
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Figure 4: R0 isoplots. Each curve shows a constant R0 value. Abscissa is lnB0; ordinate is tA.
Upper: High susceptibility, ξ = 0.5. R0 declines monotonically as B0 increases; R0 is a “single
peaked” function as tA increases. Lower: Low susceptibility: ξ = 5×10
−5. R0 again non-monotonic
with increasing tA. At lower tA, R0 increases with inoculum size before declining. r = 0.3, γ
∗
A = 0.45,
φ = 10−5.7, θ = η = 1, λ = 0.2.
probability with increasing R0 is greatest when susceptible hosts are encountered as solitaries, i.e.,
when the infection-number variance is minimal. The rate at which extinction probability increases
with G grows larger as R0 increases. Each plot in Fig. 5 includes regions where, for sufficiently
large group size, R0 > 1 but pathogen extinction is more likely than not.
The rows in Fig. 5 differ in antibiotic efficacy γ∗A; the columns differ in tA. The arithmetic
average likelihood of no secondary infection increases with γ∗A at both tA levels. The effect of
increasing tA differs between levels of γ
∗
A. At low efficacy pathogen extinction is more likely at
larger tA. But at greater efficacy, increased tA reduces the chance of no secondary infection. At
lower antibiotic efficacy, delaying treatment implies that faster within-host growth removes hosts
via mortality before therapy commences; the consequent loss of infections during therapy increases
the likelihood of no transmission. For greater antibiotic efficacy, delaying treatment implies that
the gain in new infections prior to tA outweighs the loss due to mortality; hence, earlier initiation
of the stronger antibiotic increases the chance of pathogen extinction.
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Figure 5: Probability of no secondary infections. Each plot shows probability of no new infections
as bivariate function of R0 and group size G; note directions of axes. R0 varied by varying inoculum
size B0 form 10
3 to 2 × 104. Top row: γ∗A = 0.35. Bottom row: γ
∗
A = 0.7. Left column:
tA = 4. Right column: tA = 8. In each plot, pathogen extinction less likely as R0 increases;
pathogen extinction always more likely as group size G increases. Reduction in pathogen extinction
due to increased R0 is strongest at minimal group size. Increase in extinction due to larger group
size increases at greater R0. Each plot shows a substantial region where R0 > 1, but probability of
pathogen extinction exceeds 0.5. All plots: r = 0.3, φ = 10−5.5, θ = η = 1, ξ = 0.5, λ = 0.1.
6 Discussion
Analyzing infectious-disease dynamics helps ecologists understand phenomena ranging from
microbial regulation of forest-tree diversity to propagation of novel infections in human populations
[Holdenrieder et al. 2004, Keeling and Rohani 2008, Strauss et al. 2019]. Linking within-host
pathogen growth to spread of infection among hosts [Day et al. 2011, Handel and Rohani 2015]
parallels spatial ecology in that pattern at extended scales is explained by processes at local scales
[Keeling 1999]. This paper, however, was motivated by a more mundane observation. Adults and
children, especially, take an antibiotic (often accompanied by fever-reducing medicine) routinely for
upper respiratory infections, and then return to work or school as soon as symptoms begin to
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subside. In some cases these presentees [Kivimaki et al. 2005] remain infectious, despite the
antibiotic’s effect, and they transmit disease [Siegel et al. 2007]. Removal (remaining home a few
days) would diminish transmission, though at some cost to the focal infective. A recent survey
suggests that each week nearly 3× 106 employees in the U.S. go to work sick
[Susser and Ziebarth 2016], fearing lost wages or loss of employment [DeRigne et al. 2016].
Hopefully, the model will find conceptual or practical application beyond the motivating example.
6.1 Summary of predictions
Dichotomizing the total removal process so that decreasing the time until an infection is cured may
increase the duration of infectiousness leads to several interrelated predictions, summarized here.
• Less efficacious antibiotics may increase the expected count of secondary infections beyond
the level anticipated without antibiotic intervention.
• The expected count of secondary infections is often a single-peaked function of the time since
infection when antibiotic therapy begins.
• Commencing treatment with a less efficacious antibiotic soon after infection can increase the
probability of curing the disease, but also can increase the expected count of secondary
infections. However, early treatment with a very strong antibiotic can both increase the
likelihood of curing the disease and reduce the count of secondary infections.
• The expected inoculum size across secondary infections depends on the timing of antibiotic
therapy in the primary infection, since the timing of therapy affects the counts of new
infections before and after therapy begins.
• If host are more susceptible to infection, infected-host survival and the expected count of
secondary infections decline as inoculum size increases. Given low susceptibility, secondary
infections may increase with inoculum size for small inocula before declining.
• When each susceptible individual contacts an infected host at a fixed rate, grouping
susceptibles increases the variance of the secondary-infection count and, consequently,
increases the probability of no new infection.
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The next several subsections suggest further questions about the way antibiotics might impact
linkage between within-host pathogen growth and among-host transmission.
6.2 Bacteria
Self-regulated, within-host bacterial growth could be important if antibiotics are less efficacious
against slower-growing pathogen populations [Tuomanen et al. 1986, Regoes et al. 2004]. Reduced
availability of a resource critical to a pathogen might not only decelerate growth (reducing r), but
also reduce the extra mortality imposed by the antibiotic (the model’s γ∗A). Depending on the
magnitude of the two effects, self-regulation might enhance the pathogen‘s escape from therapy.
Genetic resistance to antibiotics, often transmitted via plasmids [Lopatkin et al. 2017],
challenges control of infectious disease [Weinstein et al. 2001, Levin et al. 2014]. Phenotypic
tolerance presents related, intriguing questions [Wiuff et al. 2005]. Some genetically homogeneous
bacterial populations consist of two phenotypes; one grows faster and exhibits antibiotic sensitivity,
while the other grows more slowly and can persist after exposure to an antibiotic
[Balaban et al. 2004]. Phenotypes are not fixed; individual lineages may transition between the two
forms [Ankomah and Levin 2014]. An antibiotic’s effect on densities of the two forms might easily
extend the duration of infectiousness, but the probability of transmission, given contact, might
decline as the frequency of the persistent type increases.
6.3 Antibiotic administration
If an antibiotic is delivered periodically as a pulse, rather than dripped, the therapeutically induced
mortality of the pathogen can depend on time since the previous administration [Wiuff et al. 2005].
Complexity of the impact on the within-host dynamics could then depend on the difference
between the antibiotic’s decay rate and the pathogen’s rate of decline [O’Malley et al. 2010]. Some
authors refer to an “inoculum effect,” suggesting that antibiotic efficacy can vary inversely with
bacterial density. That is, the per capitum bacterial mortality effected by a given antibiotic
concentration declines as bacterial density increases [Levin and Udekwu 2010].
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6.4 Infected host
This paper neglects immune responses so that the duration of treatment, given cure by the
antibiotic, depends explicitly on the antibiotic’s efficacy and the age of infection when treatment
begins. Extending the model to incorporate both a constitutive and inducible immune response
would be straightforward. Following Hamilton et al. [2008], the constitutive response imposes a
constant, density-independent mortality rate on the pathogen. This response (common to
vertebrates and invertebrates) is innately fixed, its effect can be inferred by varying this paper’s
pathogen growth rate r. Induced immune responses impose density-dependent regulation of
pathogen growth; typically, pathogen and induced densities are coupled as a predator-prey
interaction [Hamilton et al. 2008]. Interaction between the time since infection when antibiotics
begin and the development time of specific memory cells of the vertebrate immune system
[Steinmeyer et al. 2010](apparently) has not been addressed.
6.5 Transmission
This paper assumes a constant (though probabilistic) rate of infectious contact with susceptible
hosts. The number of contacts available per host may be limited, so that each transmission event
depletes the local-susceptible pool [Dieckmann et al. 2000, Eames and Keeling 2002]. Regular
networks capture this effect for spatially detailed transmission, and networks with a random
number of links per host do the same when social preferences drive transmission [van Baalen 2002].
For these cases, contact structure of the susceptible population can affect both R0 and the
likelihood of pathogen extinction when rare [Caillaud et al. 2013].
Contact avoidance may sometimes be more important than contact depletion
[Reluga 2010, Brauer 2011]. If susceptible hosts recognize correlates of infectiousness, they can
avoid individuals or locations where transmission is likely. Antibiotics might extend the period of
infectiousness and, simultaneously, reduce symptom severity. As a consequence, the correlates of
infectiousness might be more difficult to detect.
6.6 Conclusion
The model emphasizes consequences of dichotomizing a host’s removal from infectiousness, and the
consequent effects on duration of infectiousness. The components of the total rate of removal, once
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antibiotic therapy begins, are no longer independent; this distinction may have consequences for
the expected number of infections per infection.
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A Appendix: Self-regulated, within-host pathogen growth
If the within-host pathogen density Bt grows logistically, then:
Bt = K
/[
1 +
(
K
B0
− 1
)
e−rt
]
(A1)
for (t ≤ tA). The carrying capacity K captures self-regulation of growth. The pathogen load is:
Ct =
K
r
ln
[
1 +
B0
K
(ert − 1)
]
; t ≤ tA (A2)
Antibiotic administration begins at tA. Pathogen density then declines exponentially,
independently of [K −B(tA)]:
B(t > tA) = K
e−(γ
∗
A
−r)(t−tA)
1 +
(
K
B0
− 1
)
e−rtA
(A3)
where γ∗A > r. If the host survives longer than time t > tA, pathogen load is:
C(t > tA) =
K
r
ln
[
1 +
B0
K
(ertA − 1)
]
+ (BtA −Bt) /(γ
∗
A − r) (A4)
Given that the host survives long enough to be cured by antibiotic therapy, the cure time is:
tC =
γ∗AtA
γ∗A − r
− ln
(
B0
θK
[
ertA +
(
K
B0
− 1
)])
(γ∗A − r)
−1 (A5)
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Expressions for infected-host survival Lt and, hence, for infection-transmission probability at
contact under logistic growth have not been simplified.
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